NASDAQ:OPTN - OptiNose Stock Price, Forecast & News

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose Inc (NASDAQ:OPTN) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.69). The business earned $12.40 million during the quarter, compared to the consensus estimate of $8.56 million. OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. View OptiNose's Earnings History.

OptiNose is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for OptiNose.

5 equities research analysts have issued 1-year price objectives for OptiNose's shares. Their forecasts range from $20.00 to $29.00. On average, they anticipate OptiNose's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 180.3% from the stock's current price. View Analyst Price Targets for OptiNose.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.

Press coverage about OPTN stock has been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. OptiNose earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for OptiNose.

Some companies that are related to OptiNose include Theravance Biopharma (TBPH), Innoviva (INVA), Intra-Cellular Therapies (ITCI), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), TG Therapeutics (TGTX), Dicerna Pharmaceuticals (DRNA), Madrigal Pharmaceuticals (MDGL), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Myovant Sciences (MYOV), Athenex (ATNX), ZEALAND PHARMA/S (ZEAL) and Opko Health (OPK).

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Idera Pharmaceuticals (IDRA), Proteostasis Therapeutics (PTI), Syndax Pharmaceuticals (SNDX), Clearside Biomedical (CLSD), Arcos Dorados (ARCO), Coherus Biosciences (CHRS), Resonant (RESN), OrganiGram (OGI), SVB Financial Group (SIVB) and Stemline Therapeutics (STML).

(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose's stock is owned by many different of retail and institutional investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.08%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.

OPTN stock was acquired by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPTN stock can currently be purchased for approximately $8.92.

OptiNose has a market capitalization of $370.91 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose.

The official website for OptiNose is http://www.optinose.com/.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]